Search results
Results from the WOW.Com Content Network
Also Read: Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point.
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer ; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer .
Exact Sciences is working on various potentially exciting products, including a multi-cancer screening test. However, the company's most promising catalysts in the next 12 months will likely still ...
Exact Sciences (NASDAQ: EXAS) Q3 2024 Earnings Call ... *Stock Advisor returns as of November 4, 2024 ... Next, our rich pipelines of new products, including OncoDetect, our blood-based CRC ...
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.
In the latest trading session, Exact Sciences (EXAS) closed at $57.56, marking a -1.96% move from the previous day.
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.